1. Scrip
  2. >>Business

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

 
• By Mandy Jackson

Allergan has two oral CGRP inhibitors – the only small molecules in the drug class in the clinic – but anti-CGRP biologics are likely to hit the market first. However, an effective oral product from a company that’s already marketing a migraine drug – Botox – could be an overlooked contender.

GoldKeyInPuzzle_1200x675

Allergan PLC’s oral small molecules ubrogepant and atogepant – in-licensed from Merck & Co. Inc. in 2015 – may be overlooked contenders in the race to bring a calcitonin gene-related peptide (CGRP) inhibitor to the market for migraine headaches.

The four leaders in the anti-CGRP field – Amgen Inc. with Novartis AG, Alder BioPharmaceuticals Inc., Eli Lilly & Co. and Teva Pharmaceutical Industries Ltd. – are developing monoclonal antibodies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.